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Systemic lupus erythematosus and systemic scieroderma are autoimmune diseases thought to
have an exogenous trigger. This review summarizes relevant case-control and cohort studies that
investigated exogenous sex hormones, silica, silicone, solvents, pesticides, mercuric chloride, and
hair dyes as putative risk factors for the development of these diseases. These studies indicate that
estrogen replacement therapy in postmenopausal women increases the risk of developing lupus,
scleroderma, and Raynaud disease, although the increase in risk is relatively modest. Oral
contraceptives may also play a role in disease susceptibility in lupus but not apparently in
scleroderma. Environmental endocrine modulators, in the form of pesticides, may represent
another opportunity for estrogenlike effects to occur, but there is scant evidence that these agents
play a role in human systemic autoimmune disease. Although exposure to silica dust increases the
risk of scleroderma in men occupied in the industry, this does not explain most male scleroderma
cases. When this exposure was investigated among women, no significant risk was found.
Additionally, silicone in implanted devices as well as occupational exposure to silicone-containing
compounds did not pose an increased risk among women for scleroderma. The role of solvent
exposure has been investigated as a risk factor for scleroderma with mixed findings. One study
suggested a potential role in male patients or in those individuals with Sc1-70 antibody positivity
either male or female. Two other studies were unable to corroborate this finding. Mercuric chloride
causes antifibrillarin antibodies and immune complex glomerulonephritis in susceptible mouse
strains. Antifibrillarin antibodies, but not glomerulonephritis, occur in a subset of scleroderma
patients and preliminary evidence suggests that mercury levels may be higher in this group of
individuals. Hair products have been studied as possibly raising the risk of developing lupus, since
such products contain an aromatic amine similar to a compound known to cause drug-induced
lupus. A 1986 study suggested a positive association, but two subsequent studies did not support
this association. Key words: environmental agents, estrogen, lupus, scleroderma, solvents,
systemic lupus erythematosus, systemic sclerosis. - Environ Health Perspect 107(suppl 5):
743-748 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/suppl-5/743-748mayes/abstract.html
Systemic lupus erythematosus (SLE, lupus)
and systemic sclerosis (sderoderma) are proto-
typical systemic autoimmune diseases affect-
ing multiple organ systems and characterized
by the presence ofautoantibodies. For the
purpose ofthis article, the term lupus will be
used to refer to the systemic form ofthe dis-
ease and the term discoid lupus will refer to
the isolated skin disease. Similarly, the term
scleroderma will be used to refer to systemic
sclerosis, not to morphea or localized sclero-
derma that is confined to the skin. These dis-
eases are considered autoimmune because
a)tissue damage is mediated by immune cells
and immune cell products; b) antibodies that
recognize elements ofhost tissue are produced
on a chronic basis; and c) there is no identified
external stimulus against which an immune
response can be considered appropriately
directed. It has long been postulated that such
an external stimulus exists and provides the
trigger or initiating event. Persistence ofdis-
ease, and perhaps its severity as well, is depen-
dent on a complex interplay between host
tissue and immune responses presumably
based on genetic features. Additionally, both
lupus and scleroderma have a female prepon-
derance, with an overall female-to-male ratio
ofapproximately 4:1 (1,2), suggesting that sex
hormones or pregnancy-related events influ-
ence diseasesusceptibility.
Thus, both genetic factors and sex
hormones are thought to play important roles
in disease risk and these features account for
the occasional familial clustering and the
strong female preponderance. However, these
two factors together make up only a small
portion ofthe risk, suggesting that some envi-
ronmental or acquired exposure(s) is neces-
sary for disease expression.
Interest in thepossibilitythatenvironmental
exposures are important in the development of
scleroderma comes from compelling evidence
that several pseudo-sderodermatous conditions
aretriggeredbythe ingestionof, orexposure to,
certain chemicals. For example, ingestion of
contaminated rape seed oil resulted in the toxic
oil syndrome in Spain in 1981 (3), and a cont-
aminated tryptophan/protein powder nutri-
tional supplement was associated with the
eosiniophilia myalgia syndrome in the United
States in the late 1980s (4). Additionally, vinyl
chloride disease occurred in heavily exposed
workers in that industry until the syndrome
was recognized andchanges made to reduce the
level ofexposure (5). All these conditions,
however, differ in many clinical features from
idiopathicscieroderma, hence the term pseudo-
scleroderma or sderodermalike conditions, and
provide limited insight into the pathogenesis of
systemicsclerosis.
Similarly in the case oflupus, a syndrome
ofdrug-induced lupus is well known and
associated with several widely used medica-
tions. In the drug-induced form of the dis-
ease, signs and symptoms are similar to, ifnot
identical with, the idiopathic disease, but the
drug-induced form is usually milder and
symptoms remit on drug cessation.
The central issue for this review is what
role, ifany, environmental exposure play in
idiopathic disease expression. Because ofthe
limited value ofcase reports and case series,
this review will focus on case-control and
cohort studies. Such studies include investiga-
tions ofexogenous sex hormones, silica, sili-
cone, solvents, mercuric chloride, and hair
dyes as potential risk factors for the develop-
ment ofthese diseases.
Exogenous Sex Hormones
and the Risk of Developing
Systemic Lupus
Because both lupus and scleroderma have a
strong female preponderance, several studies
have examined the role offemale hormones
in disease susceptibility. Table 1 summarizes
the principal findings ofthese studies.
Sanchez-Guerrero et al. (6) investigated
the association between postmenopausal estro-
gen replacement therapy and the risk ofdevel-
oping systemic lupus using data from the
Nurses' Health Study cohort, an established
cohort of women begun in 1976. These
authors reported an age-adjusted relative risk
(RR) for developing lupus in this group of2.1
(95% confidence interval [CI], 1.1-4.0) for
ever users ofestrogen and a relative risk of2.5
(95% CI, 2.5-5.0) for current users.
Additionally, risk increased with duration of
use. This analysis was based on the finding of
40 cases of definite SLE [meeting the
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Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999 743Table 1. Sex hormones and the risk of systemic lupus erythematosus or scieroderma.
Agent Author RR or aOR (95% Cl) Disease
Postmenopausal estrogen Sanchez-Guerrero et al. (25)a RR 2.1 (1.1-4.0) SLE
Postmenopausal estrogen Meier et al.(8)b RR 2.8(1.3-5.8) SLE and discoid lupus
> 24 months
Oral contraceptives Sanchez-Guerrero et al. (25)c RR 1.9(1.1-3.3) SLE
Oral contraceptives Strom et al. (10)d aOR 0.6(0.2-1.4) SLE
Oral contraceptives Beebe et al. (1l)e aOR 0.94(0.74-1.22) Scleroderma
Everpregnant Beebe et al. (1l)e aOR 0.86(0.64-1.15) Scleroderma
Postmenopausal estrogen Beebe et al. ( 1l)e aOR 1.4(1.10-1.77) Scleroderma
Postmenopausal estrogen Fraenkel et al. (12)f aOR 2.5(1.2-5.3) Raynaud phenomenon
Postmenopausal estrogen Fraenkel etal. (12)f aOR 0.9(0.3-2.6)
Abbreviations: aOR, adjusted odds ratio; Cl, confidence interval; RR, relative risk; SLE, systemuc lupus erythematosus. aNurses' Health
Studycohort, based on 30 cases ofSLE among 69,435 womenforan incidence rate of8/100,000women(6). bBased on 75 cases and 295
controls in the United Kingdom (8). cosing a more stringent diagnosis of SLE than in Sanchez-Guerrero et al. (6), based on 88 cases and
121,645controls (9). dBased on 195 cases and 143friend controls(10). Based on 472 scleroderma patients and 2,227 female controls by
random digitdialing t11). fBased on 49caseswith Raynaud phenomenon among 497 postmenopausal women.
American College ofRheumatology criteria
for the classification of lupus (7)] among
69,435 women.
Similar results were reported by Meier
et al. (8), who examined the association of
postmenopausal estrogen use with the devel-
opment of both systemic lupus and discoid
lupus, a form oflupus confined to the skin
and sometimes seen as a precursor of, or con-
comitant condition with, the systemic form.
These investigators conducted a case-control
analysis based on the General Practice
Research Database of the United Kingdom
and the resultant series consisted of75 cases
(42 cases of SLE and 34 cases of discoid
lupus) and 295 controls. The overall adjusted
RR for current users versus past and nonusers
was not elevated over that of controls.
However, analysis of long-term users, as
defined by25 or more months ofuse, showed
an adjusted RR estimate of 2.8 (95% CI,
1.3-5.8) for the development ofSLE and dis-
coid lupus combined. The RR in this study
was adjusted for body mass index, hysterec-
tomy, oophorectomy, and smoking status.
Therapy with estrogen alone (unopposed
estrogen) for greater than 24 months had an
adjusted RR of 5.3 (95% CI, 1.5-18.6),
whereas the combination of estrogen plus
progestogen had an insignificantly elevated
RR of2.0 (95% CI, 0.8-5.0). Participants in
this study were almost exclusively white; these
results should be applied with caution to a
nonwhite population.
These studies found no significant associ-
ation of smoking status, body mass index
(6,7), hysterectomy, and oophorectomy (7)
with the outcome ofSLE or discoid lupus.
In terms oforal contraceptive (OC) use
and the risk ofdeveloping SLE, Sanchez-
Guerrero et al. (9) reported a study analogous
to the hormone replacement study discussed
above, using the Nurses' Health Study cohort.
These authors found 99 cases ofdefinite SLE
and 88 cases of more stringently defined SLE
(cases meeting the American College of
Rheumatology criteria plus having a disease
diagnosis by a rheumatologist) among
121,645 women in the cohort. They reported
an RR of definite SLE of 1.4 (95% CI,
0.9-2.1) for past users of OCs. Using the
more stringent definition ofSLE, the RR was
1.9 (95% CI, 1.1-3.3). The RR estimates
were adjusted for age and postmenopausal
hormone use. No significant increase in risk
was seen with increased duration ofOC use
and no significant trend was observed accord-
ing to the time since first use. Because the
cohort was 95% white, effects of race could
not be studied and these findings may not
apply to other ethnic groups.
A smaller case-control study reported by
Strom et al. (10) of 195 SLE patients and
143 friend controls failed to find an associa-
tion between SLE and either any use or
recent use oforal contraceptives (odds ratio
[OR] = 0.6; 95% CI, 0.2-1.4).
These two studies taken together suggest
that the increased risk of developing SLE
with oral contraceptive use is relatively small
and the effect weak.
Sex Hormones and the
Risk ofScieroderma
Beebe et al. (11) studied the association
between reproductive history, OC history,
and estrogen replacement use in 472 female
scleroderma patients and 2,227 female con-
trols. These authors found that OC use did
not influence the risk ofdeveloping sclero-
derma (age and year of birth adjusted odds
ratio [aOR] = 0.94 ;95% CI, 0.74-1.22).
Additionally, earlier age of menarche (aOR
=1.00; 95% CI, 0.79-1.22) or ever being
pregnant (aOR = 0.86; 95% CI, 0.64-1.15)
were not associatedwith scleroderma.
However, estrogen replacement therapy
was associated with a small but significant
increased risk ofdisease development with an
aOR of 1.40 (95% CI, 1.10-1.77). Average
age at first use was not different between cases
and controls, suggesting that younger age at
menopause for the cases was not responsible
for this result.
Raynaud phenomenon is a reversible
vasospastic condition that causes transient
ischemia ofthe digits on cold exposure and
sometimes also with emotional stress. It is
most often seen as a primary condition in the
absence of a connective tissue disease and
affects approximately 5% of the adult
American population. The autoimmune dis-
ease with which it is most frequently associ-
ated is scleroderma, in which Raynaud
phenomenon affects 95% of cases. Primary
Raynaud disease is seen more frequently in
women than in men.
Fraenkel et al. (12) studied the association
of estrogen replacement therapy and Raynaud
phenomenon in 497 postmenopausal women
in the Framingham Offspring Study. The
prevalence of Raynaud phenomenon was
8.4% in women not taking hormone replace-
ment therapy, 19.1% in those receiving estro-
gen alone, and 9.8% in those receiving
estrogen plus progesterone. The aOR
(adjusted for age, body mass index, use of
alcohol, cigarettes, and 0-adrenoreceptor
antagonists) was 2.5 (95% CI, 1.2-5.3) with
estrogen alone and 0.9 (95% CI, 0.3-2.6)
with estrogen plus progesterone.
In summary, estrogen replacement therapy
in postmenopausal women may increase the
risk ofdeveloping lupus, scleroderma, and
Raynaud disease, although the increase in risk
is relatively modest. Evidence to date indicates
that the addition of a progestogen to estrogen
may serve to ameliorate this risk.
OCs mayplay a role in disease susceptibility
in lupus, but evidence to date suggests this is
not the case forsderoderma. Itshould be men-
tioned that these effects refer to the use of
medications before disease onset and do not
necessarily imply that the drugswould increase
theseverityofestablished disease.
The discussion above has concentrated on
the various medical uses for exogenous estro-
gens as they affect the risk of autoimmune
disease. There are potential environmental
endocrine modulators in the form ofpesti-
cides that could also influence the risk for
these diseases. Certain pesticides are known
to be endocrine disrupters including poly-
chlorinated biphenyls (PCBs), DDT metabo-
lites, and 2,3,7,8-tetrachlorodibenzo~p-dioxin
(TCDD). PCBs exert antiestrogen activity by
inhibiting estrogenmediated signal transduc-
tion (13,14). In an analogous fashion, the
longlasting metabolite of DDT (p,p-DDE)
can bind to the androgen receptor and dis-
rupt hormonal signaling (13). TCDD binds
to the aryl hydrocarbon receptor, which also
Environmental Health Perspectives * Vol 107, Supplement 5 * October 1999
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plays a role in hormonal signaling (15).
Chronic and acute exposures of mice to
TCDD have suppressed total hemolytic com-
plement and third component ofcomple-
ment levels, impairing host defenses to
bacterial pathogens (16).
At face value, this type of immuno-
suppression might be considered beneficial
for autoimmune disease. However, comple-
ment is needed for efficient clearing of
immune complexes from the circulation and
individuals with particular complement defi-
ciencies are at a higher risk for developing
lupus. Although much work has been done
on the teratogenicity and immunosuppressive
effects ofthese pesticides, little work has been
done to study potential associations between
these compounds and the risk for human
auto-immune disease.
There is a case report of scleroderma
occurring following exposure to an herbicide
combination ofbromobutyl methyl uracil,
dichlorophenyl dimethylurea, and aminotria-
zole (17). Aminotriazole can cause a contact
dermatitis (18), but none of these com-
pounds have been previously associated with
autoimmune disease. A case-control study of
472 female scleroderma cases and 2,227 con-
trols found an increased risk ofscleroderma
in those exposed (per self-report) to herbi-
cides and pesticides (aOR, 2.19; 95% CI,
1.16-4.15) but did not distinguish between
these two exposures (19).
Silica and Silicone
Occupational exposure to silica in the form of
particulate silica dust has been associated with
both the development oflupus (20) and the
development ofscleroderma [for review see
(21)]. Such occupations include mining, sand-
blasting, foundrywork, andgrindingofcertain
materials. Because these occupations usually
involve male workers, almost all reported cases
have been male. Burns et al. (22) investigated
the association between such silica exposure in
women and thedevelopment ofscleroderma in
a case-control study involving 274 female scle-
roderma cases and 1,184 female controls in
Michigan. There were 12 cases exposed com-
pared to 36 controls, with an adjusted OR of
1.50 (95% CI, 0.76-2.93). Thus, although the
numbers ofexposed individuals are small,
these data do not support an important role
for silica exposure in scleroderma disease
development inwomen.
Silman and Jones (23) found no cases of
silica exposure (by self-report or by expert
review as probable) among 56 male sclero-
derma cases in the United Kingdom.
Several epidemiologic studies have failed
to find a significant association between sili-
cone breast implants and the development of
scleroderma (22,24-27). One ofthese studies
(22) also evaluated the risk ofany implanted
medical device, including pacemakers, joint
prostheses, and indwelling catheters/shunts,
many ofwhich also include silicone products
as part ofthe device. No association with
scleroderma was found for these devices.
Additional sources ofsilicone exposure through
occupations and hobbies were examined by
these investigators, but, again, no association
was demonstrated. Silica and silicone exposure
is discussed in greaterdetail in another artide in
this monograph (28).
Solvent Exposure
Theroleoforganicsolventsandotherchemicals
has been suspected as contributing to disease
risk in scleroderma on the basis ofseveral case
reports [(17,29-45); for reviewsee Silman and
Hochberg (46)] (Table 2).
However, when these associations were
tested in case-control studies, variable results
were obtained. Nietert et al. (47) reported a
study involving 178 scleroderma patients and
200 controls from whom occupational histo-
ries were obtained. To assess solvent expo-
sure, exposure scores were computed using
job-exposure matrices based on a standard
code. Maximum intensity of exposure and
cumulative exposure were calculated. A broad
category of any solvent was used as well as
four specific solvents: trichloroethylene
(TCE), trichloroethane (TCA), carbon tetra-
chloride (CCl4), and benzene. Among men
(n = 37), those with scleroderma were more
likely than controls to have a high cumulative
intensity score (OR = 2.9; 95% CI, 1.1-7.6)
for anysolvent exposure. Men were also more
likely to have a high maximum intensity score
for TCE (but not other solvent) exposure
(OR 3.3; 95% CI, 1.0-10.3). This effect was
not seen for the women (n = 141). However,
ifthe analysis was confined to those male and
female cases who had the Scl-70 autoanti-
body (a marker for more severe disease), sig-
nificant solvent-disease associations were
observed.
Somewhat at variance with these results is
the report by Lacey et al. (48) of a case-
control study of 472 female scleroderma
patients and 2,227 controls in Ohio and
Michigan, which reported a significantly
increased risk ofscleroderma in those with
self-reported occupational activities ofprofes-
sional cleaning or maintenance (aOR =2.18;
95% CI, 1.48-3.22). These activities are
more likely to provide exposure to water-
based solutions, than organic solvents. These
investigators did not find a significant associa-
tion with dry cleaning (aOR = 1.46; 95% CI,
0.91-2.34) or with TCE exposure (aOR =
2.29; 95%, CI 0.92-5.71). Paint thinners
and removers were significantly associated
with disease development (aOR = 1.82; 95%
CI, 1.32-2.51). These last solvents are mix-
tures ofhydrocarbons ofvarying molecular
weights but with properties distinct from the
chlorinated hydrocarbon solvents TCE,
TCA, or CC14.
Silman and Jones (23) reported an
occupational analysis of56 men with sclero-
derma in the United Kingdom compared to
97 controls (56 age- and geographic area-
matched patients without connective tissue
disease from general practitioners and 41
friend controls). Job histories and detailed
descriptions and information regarding the
specific agents vinyl chloride, polyvinyl chlo-
ride, silica, organic solvents, epoxy resins,
and formaldehyde were obtained. Analysis
was performed based on self-report as well as
expert review. No significantly elevated ORs
Table 2. Summary of case reports and case series suggesting a relationship between environmental exposures and
systemic sclerosis, exclusive of mining.a
Date of Author No. of
report (reference) patients Agent Country
1957 Reinl (29) 1 Trichloroethylene U.S.
1977 Fessel(3L) 1 Welding U.S.
1980 Yamakage et al. (31) 2 Polymerization of epoxy resins Japan
1986 Rush and Chaiton (32) 1 Urea formaldehyde U.S.
1987 Lockey et al. (33) 1 Trichloroethylene U.S.
1987 Czirjak etal. (34) 8 Aromatic solventsb Hungary
1987 Czirjak and Szegedi (35) 1 Benzene Hungary
1988 Owens and Medsger(36) 2 m-Phenylenediamine U.S.
1990 Mehlhorn et al. (37) 1 Scouring powder with crystalline silica Germany
1991 Brasington and Thorpe-Swenson (38) 1 Organic solventsc U.S.
1992 Pelmear etal. (39) 1 Welding Canada
1992 Yanez-Diaz etal. (40) 1 Trichloroethylene Spain
1992 Tibon-Fisher et al. (41) 1 Trichloromethane Israel
1994 Dunnill and Black(17) 1 Herbicided England
1996 Inachi etal. (42) 1 Epoxy resins Japan
1997 Zachariae et al. (43) 13 Organic solventse Denmark
1998 Attoussi et al. (44) 1 Cocaine U.S.
1998 Biasi et al. (45) 1 Talc and heroin France
'This table is limited to reports of systemic sclerosis, not localized scleroderma and not sclerodermalike disorders. bVarious aromatic
organic solvents. cSolvents included trichloroethane, xylene, trimethylbenzene, and naphthalene. dlerbicide contained bromacil or
bromobutyl methyl uracil, diuron ordichlorophenyl dimethylurea, and aminotriazole. 'Notwell characterized.
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Exposure to organic solvents was stratified
on duration of use but no significant trend
of increasing OR was found compared with
either control group, with most ORs center-
ing around unity. Table 3 is a summary of
these results.
A study by Kilburn and Warshaw (49)
reported an increase in the prevalence of some
SLE symptoms as well as an increase in antinu-
dearbodies in a group ofindividuals inTucson,
Arizona, exposed to water contaminated with
TCE, TCA, inorganic chromium, and other
chemicals. This report is difficult to interpret
because of concerns regarding exposure misclas-
sification and caseandcontrol selection.
The role that solvents may play in disease
initiation is unclear. Data from animal studies
demonstrate that some solvents and/or their
metabolites can bind to nucleic acids and
proteins (50,51) and can reduce both the
humoral and cell-mediated response (52-54).
Additionally, exposure to TCE and one ofits
metabolites (dichloroacetyl chloride) induced
autoantibody formation in genetically suscep-
tible autoimmune-prone MRL +/+ mice (55).
Byers et al. (56) studied a human population
exposed to TCE in the water supply and
found elevated levels ofT lymphocytes as well
as elevated levels of CD4+ and CD8+ cells,
suggesting that this agent or its metabolites
could alter human immunity. This study did
not address the issue ofautoimmune disease
in this population. The role ofsuch solvents
in inducing or accelerating scleroderma or
lupus remains unclear, as noted in the discus-
sion above ofthe case-control studies.
Mercuric Chloride
Mercuric chloride is an immunomodulating
agent that causes immune complex glomeru-
lonephritis and autoantibody production in
susceptible mouse strains (57,58). The
autoantibody produced recognizes a nudeolar
protein, fibrillarin (59). Evidence from
Arnette et al. (60) suggests that mercury
modifies fibrillarin leading to autoantigenic-
ity, which then induces a persistent self-reac-
tion to the native or unmodified fibrillarin.
Antifibrillarin antibodies are found in only
8% ofscleroderma patients, and, although
relatively infrequent in occurrence, are associ-
atedwith more severe disease.
Urinary mercury excretion has been
reported to be higher in sderoderma patients
who are positive for antifibrillarin antibodies
than in antifibrillarin-negative patients or nor-
mal controls (61). These levels, however, were
still in the normal or unexposed range, as
would be expected in individuals who showed
no signs or symptoms of mercury toxicity.
Also, neither scleroderma patients in general
nor antifibrillarin antibody-positive sclero-
derma patients develop immune complex
glomerulonephritis.
Hair Products
Drugs that contain aromatic amines can
induce an SLE-like syndrome [for review see
Price andVenables (62)]. Some hair products,
including hair dyes, straighteners, and perma-
nents, contain the aromatic amine hydrazine,
some ofwhich can be absorbed through the
scalp. This observation prompted the investi-
gation ofenvironmental exposures to similar
compounds and the risk ofdeveloping lupus.
The use ofhair dyes was initially reported in
1986 to increase the riskfor SLE (63), but this
finding has not been confirmed in two larger
and more recent studies. In the 1986 study,
Freni-Titulaer et al. (63) reported a positive
association between hair product use and con-
nective tissue disease in southeastern Georgia.
However, in 1992 Petri and Allbritton (64)
Table 3. Case-control studies regarding solvents and scieroderma.
Agent
All solvents
Trichloroethylene
Trichloroethylene
Paintthinners/removers
Professional cleaning
(water-based solutions)
Solvents
Solvents
Solvents
Solvents
Study
Nietert(47)a
Nietert (47)a
Nietert(47)a
Lacey (48)b
Lacey(48)b
Lacey(48)b
RR (95% Cl)
2.911.1-7.6)
3.3 (1.0-10.3)
4.4(1.3-15.0)
2.29(0.92-5.71)
1.82 (1.32-2.51)
2.18 (1.48-3.22)
Silman (23)c 1.7(0.7-4.1)
2.3 (0.9-6.2)
Silman (23)c 1.3(0.6-2.7)
Silman (23)c 2.3(0.9-6.2)
Comments
Men only, cumulative intensity
Men only, maximum intensity
Scl-70-positive women, cumulative
intensity
Women only, self-report
Women only, self-report
Women only, self-report
Male cases/GP controls
self-report
Male cases/friend controls
self-report
Male cases/GP controls
expert reviewed
Male cases/friend controls
reported their study ofhair product use and
the risk ofdevelopment oflupus as well as the
risk ofhaving more severe disease. The patient
group consisted of 218 members of the
Hopkins Lupus Cohort; controls were sex-
matched and age-similar relatives (n = 178) or
friends (n = 186). The study reported no sig-
nificant difference in exposure to hairdye, hair
straightener, orhair permanent, and no signifi-
cant differences in measures of SLE disease
activity in patients who used these hair prod-
ucts after their diagnosis versus those who did
not use the products.
Sanchez-Guerrero et al. (65), using the
Nurses' Health Study Cohort (106,391 par-
ticipants), found similar results, i.e., no evi-
dence for an association between lupus
(n = 85 cases) and the prior use ofpermanent
hair dye (age-adjusted RR = 0.96; 95% CI,
0.63-1.47) for ever users versus never users.
Additionally, women with 15 or more years
of use had no increased risk (RR = 0.92 [95%
CI, 0.46-1.83]).
Summary
There is a relative paucity ofcase-control or
cohort studies investigating environmental
exposures and the risk ofdeveloping the sys-
temic autoimmune diseases lupus and sclero-
derma, in large part because these diseases are
relatively rare. In total, the current state ofthe
risk factor analysis suggests that no currently
known exposure or combination of exposures
explains an important proportion of the
occurrence ofeither lupus or scleroderma.
The cause of these chronic diseases is
unknown and the situation is douded by the
fact that there could be multiple triggers for
these diseases.
Current evidence supports the finding
that estrogen replacement therapy increases
the risk (approximately 1.5- to 3-fold) of
developingsystemic and discoid lupus, sclero-
derma, and Raynaud disease. The use of
estrogen-progestogen combination therapy
may ameliorate this risk. Oral contraceptives
may double the risk for SLE, but there is lack
of evidence to support this conclusion for
scleroderma.
Silica exposure does not explain most
male cases of scleroderma and does not
appear to play a significant role in sclero-
derma risk in women. The role ofsolvent
exposure, particularly in raising the risk for
scleroderma in men who have a higher preva-
lence ofsuch occupations, remains unclear.
Hair products do not appear to raise the risk
ofSLE, contrary to earlier reports.
Mechanisms
Potential mechanisms of induction of
autoimmunity for these diverse environmen-
tal agents can be classified into three broad
categories: a) a change in the hormonal
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milieu to favor estrogenic stimulation ofthe
immune system; b) suppression ofone section
ofthe immune system (such as complement
levels), which disrupts normal immune sur-
veillance; and c) chemical binding to a self-
antigen forming a neoantigen, thus breaking
tolerance by inducing immunity to the
unmodified native molecule as well as to the
modified antigen.
These mechanisms are currently speculative
at best but are supported by animal models. It
should be noted that the induction ofautoanti-
bodies does not necessarily result in the expres-
sion of autoimmune disease. Many of the
autoantibodies are considered markers ofdis-
ease with no known role in tissue damage.
Several family studies have found that appar-
endyhealthy family members and even spouses
oflupus and scleroderma patients may have
these autoantibodies but seldom express dis-
ease. This may reflect a shared environmental
exposure but the lack ofthe specific genes
required forthe "correct" immune response.
Opportunities for Future
Research
This review is relatively brief because the
number of well-designed epidemiologic
studies in this field is small. The existence of
large population cohorts as well as an estab-
lished patient cohort for scleroderma (includ-
ing the Scleroderma Registry, Wayne State
University, Division of Rheumatology,
Detroit, Michigan) should facilitate this
research. Other potential exposures such as
herbicides, pesticides, and mercury, as well as
exposures to infectious agents, need to be
investigated. More detailed studies ofoccupa-
tional and environmental exposures are
clearly warranted by preliminary data and are
currently feasible given the interest ofthe sci-
entific community and availability oflarge
patient cohorts.
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